SARcode Bioscience, Inc.

ANN ARBOR, Mich., May 9, 2023 /PRNewswire/ -- SARC (Sarcoma Alliance for Research Through Collaboration) is proud to announce that it has launched a national, virtual multidisciplinary sarcoma tumor board. As the care of patients with cancer, particularly uncommon cancers such as sarcoma, becomes increasingly complex and therapeutic options become more nuanced, input of multiple expert clinicians is more critical than ever for educated, optimal decision making for the treating physicians and surgeons. Continue Reading Virtual, national tumor board enables physicians & surgeons to get expert guidance on how to treat sarcomas Tweet this The SARC Multidisciplinary Tumor Board (SMTB) brings together sarcoma experts, complementing and expanding the geographic reach of local or regional institutional tumor boards. The SMTB provides a uniquely focused forum for physicians and surgeons to present sarcoma patient cases for in-depth, evidence-based discussion of tumor diagnosis and management of adults and children before or after diagnostic procedures, biopsies, surgery, or at relapse. "We are excited about our SARC Multi-Disciplinary Tumor Board," said Dr. Scott Okuno, SARC's Chief Medical Officer and Professor of Oncology at Mayo Clinic, "as this allows all sarcoma providers, regardless of whether they are practicing in a small, geographically remote center or a major center, to get opinions how to treat and manage all types of bone and soft tissue sarcoma from experts in the sarcoma field." "In 2023 SARC proudly celebrates our twentieth year facilitating and driving team science," said Steven Young, President & CEO of SARC, "and this tumor board extends support to the broader clinical community." For more information, or to submit cases for consideration, clinicians are directed to: . About SARC SARC (Sarcoma Alliance for Research Through Collaboration) is a US-based, non-profit (501(c)(3)) organization dedicated to fostering progress in the prevention and treatment of sarcoma to improve patient outcomes and ultimately find a cure. SARC was formed by the sarcoma research community in 2003 to bring together the best cancer centers in the world supported by centralized infrastructure for the conduct of multi-institutional collaborative sarcoma research. Since founding, SARC has fast-tracked and sponsored twenty-six Phase I, II and III clinical trials along with correlative studies to better understand the biologic bases for what drugs and combinations are most effective in treating sub-groups of patients, young investigator mentorship and grants programs, and the investigation of key biological questions across nearly 90 medical centers with specialized sarcoma programs in the United States and overseas. To learn more about the SARC organization, its impactful programs and innovative investigator-initiated clinical trials, and how to help support its mission, please visit the SARC website at . What Is Sarcoma? Sarcomas are cancers of the bony skeleton (the skull, vertebrae, ribs, and extremities), and the so-called soft tissues, including muscle and fat. Sarcomas are disproportionately common in children and young adults but occur at all ages. There are many different types of sarcomas, leading to diagnostic and therapeutic challenges. SARC and our collaborators are working to advance the science and treatment of sarcomas. SOURCE SARC

ANN ARBOR, Mich., May 9, 2023 /PRNewswire/ -- SARC (Sarcoma Alliance for Research Through Collaboration) is proud to announce that it has launched a national, virtual multidisciplinary sarcoma tumor board. Virtual, national tumor board enables physicians & surgeons to get expert guidance on how to treat sarcomas As the care of patients with cancer, particularly uncommon cancers such as sarcoma, becomes increasingly complex and therapeutic options become more nuanced, input of multiple expert clinicians is more critical than ever for educated, optimal decision making for the treating physicians and surgeons. The SARC Multidisciplinary Tumor Board (SMTB) brings together sarcoma experts, complementing and expanding the geographic reach of local or regional institutional tumor boards. The SMTB provides a uniquely focused forum for physicians and surgeons to present sarcoma patient cases for in-depth, evidence-based discussion of tumor diagnosis and management of adults and children before or after diagnostic procedures, biopsies, surgery, or at relapse. "We are excited about our SARC Multi-Disciplinary Tumor Board," said Dr. Scott Okuno, SARC's Chief Medical Officer and Professor of Oncology at Mayo Clinic, "as this allows all sarcoma providers, regardless of whether they are practicing in a small, geographically remote center or a major center, to get opinions how to treat and manage all types of bone and soft tissue sarcoma from experts in the sarcoma field." "In 2023 SARC proudly celebrates our twentieth year facilitating and driving team science," said Steven Young, President & CEO of SARC, "and this tumor board extends support to the broader clinical community." For more information, or to submit cases for consideration, clinicians are directed to: . About SARC SARC (Sarcoma Alliance for Research Through Collaboration) is a US-based, non-profit (501(c)(3)) organization dedicated to fostering progress in the prevention and treatment of sarcoma to improve patient outcomes and ultimately find a cure. SARC was formed by the sarcoma research community in 2003 to bring together the best cancer centers in the world supported by centralized infrastructure for the conduct of multi-institutional collaborative sarcoma research. Since founding, SARC has fast-tracked and sponsored twenty-six Phase I, II and III clinical trials along with correlative studies to better understand the biologic bases for what drugs and combinations are most effective in treating sub-groups of patients, young investigator mentorship and grants programs, and the investigation of key biological questions across nearly 90 medical centers with specialized sarcoma programs in the United States and overseas. To learn more about the SARC organization, its impactful programs and innovative investigator-initiated clinical trials, and how to help support its mission, please visit the SARC website at . What Is Sarcoma? Sarcomas are cancers of the bony skeleton (the skull, vertebrae, ribs, and extremities), and the so-called soft tissues, including muscle and fat. Sarcomas are disproportionately common in children and young adults but occur at all ages. There are many different types of sarcomas, leading to diagnostic and therapeutic challenges. SARC and our collaborators are working to advance the science and treatment of sarcomas. View original content to download multimedia: SOURCE SARC

Bay Area's HealthQuest Capital Debuts With $110 Million With Healthcare, Medtech Focus August 19, 2014 By Krystle Vermes, BioSpace.com Breaking News Staff Today, California-based investment company HealthQuest Capital announced the end of its debut fund at the hard cap of $110 million. This is an excess of its original target fund of $50 million. "HealthQuest is focused on funding innovation that can be quantified in terms of both improvements in patient outcomes as well as healthcare economics,” said HealthQuest Founding Managing Partner, Garheng Kong. “We believe these opportunities can deliver valuable medical advances that translate into excellent financial returns.” Kong founded HealthQuest Capital in 2013. He has been an investor in the industry since 2000. Some of the companies Kong has invested in include Cellective Therapeutics, Novamin Technologies, Cempra Pharmaceuticals, Serenex and Alimera Sciences. Most recently, he has invested in Histogenics, Salveo Specialty Pharmacy, SARcode Bioscience Inc. and First Aid Shot Therapy. Now, Kong is shifting his focus to his own company. "We are excited to launch our debut fund, and appreciate the support of our investors for the HealthQuest strategy and team,” Kong continued. Following this round of funding, HealthQuest is expected to focus on areas of the healthcare community where there is unmet clinical need for innovation. The HealthQuest investor team includes Randy Scott, Founder and CEO of Novamin Technologies; David Kabakoff, Co-founder, CEO and Chairman of Salmedix and Chairman of Trius; and Venture Partner Tom Callaway, President and Founder of Life Science Partner. HealthQuest views itself as a “venture growth” fund, seeking commercial stage investments. The company will not take “binary risks” such as clinical studies or regulatory submissions where its investments represent an “all or nothing” bet. Instead, HealthQuest will focus on growing revenues and scaling the company over time through its investments. Currently, HealthQuest has partners in California, Florida and Georgia. The company is considering investments from all parts of North America. Its target sectors include medical devices, diagnostics, consumer/OTC health, patient care products, mHealth and Health IT that directly impacts patient treatment or care. Additionally, HealthQuest gives preference to companies that need less than $20 million to achieve profitability. Its initial investment is typically between $2 to 4 million. HealthQuest is a part of the Sofinnova Ventures network, which has been making investments for more than 40 years. Its investment capabilities have been extended through its partnership with Sofinnova Ventures to three continents around the world.